KR101072339B1 - 프로스타시클린 유사체의 전달을 위한 화합물 및 방법 - Google Patents

프로스타시클린 유사체의 전달을 위한 화합물 및 방법 Download PDF

Info

Publication number
KR101072339B1
KR101072339B1 KR1020057022319A KR20057022319A KR101072339B1 KR 101072339 B1 KR101072339 B1 KR 101072339B1 KR 1020057022319 A KR1020057022319 A KR 1020057022319A KR 20057022319 A KR20057022319 A KR 20057022319A KR 101072339 B1 KR101072339 B1 KR 101072339B1
Authority
KR
South Korea
Prior art keywords
treprostinil
group
substituted
compound
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020057022319A
Other languages
English (en)
Korean (ko)
Other versions
KR20060021862A (ko
Inventor
켄 파레스
데이비드 모톨라
Original Assignee
유나이티드 쎄러퓨틱스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34079029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101072339(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 유나이티드 쎄러퓨틱스 코포레이션 filed Critical 유나이티드 쎄러퓨틱스 코포레이션
Publication of KR20060021862A publication Critical patent/KR20060021862A/ko
Application granted granted Critical
Publication of KR101072339B1 publication Critical patent/KR101072339B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C07C59/13—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020057022319A 2003-05-22 2005-11-22 프로스타시클린 유사체의 전달을 위한 화합물 및 방법 Expired - Lifetime KR101072339B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47240703P 2003-05-22 2003-05-22
US60/472,407 2003-05-22
PCT/US2004/016401 WO2005007081A2 (en) 2003-05-22 2004-05-24 Compounds and methods for delivery of prostacyclin analogs

Publications (2)

Publication Number Publication Date
KR20060021862A KR20060021862A (ko) 2006-03-08
KR101072339B1 true KR101072339B1 (ko) 2011-10-11

Family

ID=34079029

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057022319A Expired - Lifetime KR101072339B1 (ko) 2003-05-22 2005-11-22 프로스타시클린 유사체의 전달을 위한 화합물 및 방법

Country Status (8)

Country Link
US (19) US7417070B2 (enExample)
EP (2) EP2792353B1 (enExample)
JP (2) JP5043433B2 (enExample)
KR (1) KR101072339B1 (enExample)
CN (4) CN101265226B (enExample)
CA (4) CA2851309C (enExample)
ES (2) ES2622471T5 (enExample)
WO (1) WO2005007081A2 (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10214983A1 (de) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
CN101265226B (zh) 2003-05-22 2013-04-24 联合治疗公司 化合物和释放前列环素类似物的方法
DE602004022982D1 (de) * 2003-12-16 2009-10-15 United Therapeutics Corp Verwendung von treprostinil zur verbesserung der nierenfunktion
US20090124697A1 (en) * 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
CA2549724C (en) * 2003-12-16 2014-02-11 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
ATE462427T1 (de) 2004-04-12 2010-04-15 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
KR20080029962A (ko) * 2005-06-02 2008-04-03 더 리젠츠 오브 더 유니버시티 오브 콜로라도 프로스타사이클린 유사체의 용도
US8747897B2 (en) * 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
KR101390579B1 (ko) 2006-05-15 2014-05-19 유나이티드 세러퓨틱스 코오포레이션 정량 흡입기를 사용한 트레프로스티닐 투여
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
US20090036465A1 (en) * 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008088617A1 (en) * 2006-12-04 2008-07-24 Regents Of The University Of Colorado Treatment of copd
EP2120961A1 (en) * 2007-02-09 2009-11-25 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
KR20160048222A (ko) * 2007-12-17 2016-05-03 유나이티드 세러퓨틱스 코오포레이션 레모둘린?의 활성 성분인 트레프로스티닐의 개선된 제조 방법
ES2575565T3 (es) * 2008-05-08 2016-06-29 United Therapeutics Corporation Procedimiento para la preparación de monohidrato de treprostinilo y su utilización para el almacenamiento y el envío
US20110294815A1 (en) * 2008-06-27 2011-12-01 Harbeson Scott L Prostacyclin analogs
KR101544246B1 (ko) * 2009-05-07 2015-08-12 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린 유사체의 고체 제제
CN101891596B (zh) * 2009-05-22 2013-12-11 上海天伟生物制药有限公司 一种化合物及其制备方法和用途
DE102009031274A1 (de) 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
KR101729800B1 (ko) * 2009-08-07 2017-04-24 에스씨아이팜 에스에이알엘 낭포성 섬유증의 치료를 위한 조성물
EP3108888B1 (en) 2010-03-15 2020-02-12 United Therapeutics Corporation Treatment for pulmonary hypertension
CA2777070C (en) 2010-06-03 2019-11-05 United Therapeutics Corporation Treprostinil production
US20120004307A1 (en) * 2010-06-15 2012-01-05 United Therapeutics Corporation Oral treatment of digital ischemic lesions
CA2710725C (en) 2010-07-22 2017-08-01 Alphora Research Inc. Protected aldehydes for use as intermediates in chemical syntheses, and processes for their preparation
CA2726599C (en) 2010-12-30 2017-07-25 Alphora Research Inc. Process for treprostinil salt preparation
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
EP2681204B1 (en) 2011-03-02 2016-04-27 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
CN103193627B (zh) * 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
US9387214B2 (en) 2012-01-13 2016-07-12 United Therapeutics Corporation Method of identifying therapies for pulmonary hypertension
ES2639823T3 (es) * 2012-06-15 2017-10-30 Scipharm Sàrl Proceso para la preparación de treprostinilo y derivados del mismo
JP6357481B2 (ja) * 2012-11-30 2018-07-11 インスメッド， インコーポレイテッド プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法
CN104837806A (zh) * 2012-12-07 2015-08-12 开曼化学股份有限公司 前列环素类似物的合成方法
CN106831680B (zh) * 2012-12-20 2020-01-17 江苏盛迪医药有限公司 一种制备曲前列尼尔的中间体、其制备方法以及通过其制备曲前列尼尔的方法
EP3712142B1 (en) * 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
WO2014159050A1 (en) * 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
CN109608326A (zh) * 2013-03-15 2019-04-12 联合治疗公司 曲前列环素的盐
WO2014160638A1 (en) 2013-03-25 2014-10-02 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
CN105407883A (zh) 2013-04-30 2016-03-16 联合治疗学有限公司 控释药物制剂
EP3808731A1 (en) 2013-10-25 2021-04-21 Insmed Incorporated Prostacyclin compounds
US9895465B2 (en) * 2014-03-12 2018-02-20 Pioneer Surgical Technology, Inc. Absorbable compositions and methods for their use in hemostasis
US20170095432A1 (en) 2014-06-13 2017-04-06 United Therapeutics Corporation Treprostinil formulations
WO2016010538A1 (en) 2014-07-16 2016-01-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
WO2016038532A1 (en) 2014-09-09 2016-03-17 Mylan Laboratories Limited Amorphous treprostinil diethanolamine
HU231184B1 (hu) * 2014-10-08 2021-07-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Treprostinil-nátrium-monohidrát és eljárás ennek előállítására
US9593061B2 (en) 2014-10-20 2017-03-14 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
CA2967385C (en) * 2014-11-18 2023-05-16 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
TWI540121B (zh) * 2014-12-01 2016-07-01 臺灣永光化學工業股份有限公司 曲前列環素二乙醇胺之合成方法及新穎中間體
WO2016088119A1 (en) 2014-12-03 2016-06-09 Steadymed Ltd Preservative-free treprostinil formulations and methods and devices for use with same
CN104783298A (zh) * 2015-03-24 2015-07-22 湖州珍贝羊绒制品有限公司 一种生物灭菌组合物及其纳米乳的制备与应用
WO2016176555A1 (en) * 2015-04-29 2016-11-03 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11069054B2 (en) 2015-12-30 2021-07-20 Visiongate, Inc. System and method for automated detection and monitoring of dysplasia and administration of immunotherapy and chemotherapy
WO2017192993A1 (en) 2016-05-05 2017-11-09 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
EP3512495B1 (en) * 2016-09-15 2022-11-09 Camurus AB Prostacyclin analogue formulations
JP7220650B2 (ja) * 2016-09-26 2023-02-10 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
CA3045917A1 (en) 2016-12-05 2018-06-14 Corsair Pharma, Inc. Dermal and transdermal administration of treprostinil and salts thereof
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
EP3498283A1 (en) * 2017-12-14 2019-06-19 Ipsol AG Glycosidic derivatives of treprostinil
HU231296B1 (hu) 2018-03-09 2022-09-28 Chinoin Zrt Eljárás treprostinil-dietanol-amin só B polimorf formájának előállítására
AU2019266171B2 (en) * 2018-05-07 2021-10-28 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of treprostinil
CA3112986C (en) * 2018-09-18 2024-06-18 Eli Lilly And Company Erbumine salt of treprostinil
US11458098B2 (en) 2019-04-29 2022-10-04 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
JP2020011957A (ja) * 2019-07-22 2020-01-23 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
CN114616225A (zh) * 2019-08-23 2022-06-10 联合治疗公司 曲前列环素前药
US10781160B1 (en) * 2019-10-04 2020-09-22 Chirogate International Inc. Hexadecyl Treprostinil crystals and methods for preparation thereof
EP4076398A4 (en) 2019-12-16 2024-01-03 Tenax Therapeutics, Inc. LEVOSIMENDAN TO TREAT PULMONARY HYPERTENSION ACCOMPANIED BY HEART FAILURE BY MEANS OF PRESERVED EJECTION FRACTION (PH-HF-PEF)
US11826327B2 (en) 2020-04-17 2023-11-28 United Therapeutics Corporation Treatment for interstitial lung disease
WO2021252446A1 (en) 2020-06-09 2021-12-16 United Therapeutics Corporation Fumaryl diketopiperidine prodrugs of treprostinil
JP7138685B2 (ja) * 2020-10-26 2022-09-16 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
KR20230096998A (ko) * 2020-10-28 2023-06-30 인스메드 인코포레이티드 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법
US11447440B2 (en) 2020-10-29 2022-09-20 Chirogate International Inc. Treprostinil monohydrate crystals and methods for preparation thereof
JP2023553989A (ja) * 2020-12-14 2023-12-26 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグで疾患を治療する方法
AU2022229367A1 (en) 2021-03-03 2023-09-14 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
CN113552265B (zh) * 2021-09-17 2022-01-04 天地恒一制药股份有限公司 富马酸丙酚替诺福韦合成原料中杂质的检测方法及应用
EP4456897A4 (en) 2021-12-31 2025-12-10 Tenax Therapeutics Inc ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
CN116444377A (zh) * 2022-01-07 2023-07-18 广州楷石医药有限公司 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途
KR20240141319A (ko) 2022-02-08 2024-09-26 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 일로프로스트 조합 치료 요법
EP4516297A1 (en) 2022-04-29 2025-03-05 Zhaoke Pharmaceutical (Guangzhou) Co., Ltd Treprostinil soft mist inhalant
WO2024097125A1 (en) 2022-10-31 2024-05-10 United Therapeutics Corporation Methods for treating pulmonary hypertension
KR20250139830A (ko) 2023-01-19 2025-09-23 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 유사체
CN117800845A (zh) * 2023-03-28 2024-04-02 广州楷石医药有限公司 一种羟基取代曲前列尼尔衍生物、合成方法及其应用
WO2025034784A1 (en) 2023-08-08 2025-02-13 United Therapeutics Corporation A method of producing an oral osmotic pharmaceutical delivery system and a pharmaceutical batch produced using the same
US20250197338A1 (en) 2023-11-09 2025-06-19 United Therapeutics Corporation Syntheses of compounds useful for producing treprostinil

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057701A1 (en) * 1999-03-31 2000-10-05 United Therapeutics Corporation Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US515322A (en) * 1894-02-27 Railroad-car
US3515222A (en) * 1968-06-19 1970-06-02 American Tractor Equip Corp Cable plow mounting
US4490537A (en) * 1977-04-19 1984-12-25 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
US4338457A (en) * 1980-02-28 1982-07-06 The Upjohn Company Composition and process
CA1201712A (en) * 1980-02-28 1986-03-11 Paul A. Aristoff Carbacyclin analogs
US4525586A (en) 1980-02-28 1985-06-25 The Upjohn Company Composition and process
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
US4420632A (en) 1980-04-15 1983-12-13 The Upjohn Company Composition and process
US4306076A (en) * 1980-04-23 1981-12-15 The Upjohn Company Inter-phenylene CBA compounds
US4349689A (en) * 1980-12-22 1982-09-14 The Upjohn Company Methano carbacyclin analogs
US4434164A (en) 1981-06-01 1984-02-28 Pfizer Inc. Crystalline benzothiazine dioxide salts
US4486598A (en) 1982-02-22 1984-12-04 The Upjohn Company Carbacyclin analogs
DE3315356A1 (de) * 1982-04-30 1983-11-17 Ono Pharmaceutical Co. Ltd., Osaka Verwendung von prostaglandinanalogen
US4561604A (en) 1983-07-18 1985-12-31 Shimano Industrial Company Limited Spinning reel
FI67490C (fi) 1983-11-02 1985-04-10 Fluilogic Systems Oy Filtreringsenhet
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US4668814A (en) * 1984-03-08 1987-05-26 The Upjohn Company Interphenylene carbacyclin derivatives
US4683330A (en) 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
CA1241324A (en) 1984-03-08 1988-08-30 Paul A. Aristoff Interphenylene carbacyclin derivatives
DE3427797A1 (de) * 1984-07-25 1986-02-06 Schering AG, 1000 Berlin und 4709 Bergkamen Zytoprotektive wirkung von prostacyclin-derivaten an leber, bauchspeicheldruese und niere
US5663203A (en) * 1986-09-11 1997-09-02 Schering Aktiengesellschaft Agents containing prostacyclin derivatives for topical application
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
GB8824187D0 (en) 1988-10-14 1988-11-23 Wellcome Found Compounds for use in medicine
US5545671A (en) * 1989-10-05 1996-08-13 Schering Aktiengesellschaft Antimetastically acting agents
GB9011588D0 (en) * 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
DE4104606C1 (enExample) * 1991-02-12 1992-10-15 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
US5496850A (en) * 1991-04-11 1996-03-05 Toray Industries, Inc. Antimetastasis agent of malignant tumors
DE4135193C1 (enExample) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
US5190972A (en) 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
DE4202665A1 (de) 1992-01-28 1993-07-29 Schering Ag Prostacyclin- und carbacyclinderivate als mittel zur behandlung von multipler sklerose
US6171786B1 (en) 1992-09-17 2001-01-09 Board Of Trustees Of University Of Illinois Methods for preventing multidrug resistance in cancer cells
US5466203A (en) * 1994-03-30 1995-11-14 Chen; George Magnetically controlled load adjusting structure of gymnastic apparatus
DE69735002T2 (de) 1996-10-25 2006-10-26 Shire Laboratories, Inc. Osmotisches Verabreichungssystem für lösliche Dosen
DK0947196T3 (da) 1997-03-14 2009-10-12 Toray Industries Fremstilling med langvarig frigivelse af et prostaglandin I-derivat
US6451815B1 (en) 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
GB9718903D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6441245B1 (en) * 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
CA2307163C (en) 1997-10-24 2014-05-06 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
CN1142781C (zh) 1997-11-14 2004-03-24 联合治疗公司 9－脱氧－2′,9－α－亚甲基－3－氧杂－4,5,6－三去甲－3,7－(1′,3′－间亚苯基)－13,14－二氢－前列腺素F1在治疗外周血管疾病中的用途
US20010038855A1 (en) 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE377645T1 (de) * 1999-03-18 2007-11-15 Queen Mary & Westfield College Inhibitoren der endothelin-1 synthese
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6242482B1 (en) * 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
EP1311294A2 (en) * 2000-08-04 2003-05-21 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
WO2002055136A2 (en) 2000-12-01 2002-07-18 Nephros Therapeutics Inc Intrasvascular drug delivery device and use therefor
US6700025B2 (en) * 2001-01-05 2004-03-02 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US20030108512A1 (en) * 2001-12-10 2003-06-12 Robert Shorr Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the treatment of cancer
US6803386B2 (en) * 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
US7132453B2 (en) 2002-03-15 2006-11-07 Vanderbilt University Method of using prostacyclin to treat respiratory syncytial virus infections
DE10214983A1 (de) 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
CN101265226B (zh) * 2003-05-22 2013-04-24 联合治疗公司 化合物和释放前列环素类似物的方法
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
US20050254032A1 (en) * 2003-11-13 2005-11-17 Fuji Photo Film Co., Ltd. Exposure device
CA2549724C (en) 2003-12-16 2014-02-11 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
EP2120961A1 (en) 2007-02-09 2009-11-25 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
KR20160048222A (ko) * 2007-12-17 2016-05-03 유나이티드 세러퓨틱스 코오포레이션 레모둘린?의 활성 성분인 트레프로스티닐의 개선된 제조 방법
ES2575565T3 (es) * 2008-05-08 2016-06-29 United Therapeutics Corporation Procedimiento para la preparación de monohidrato de treprostinilo y su utilización para el almacenamiento y el envío
JP2010244388A (ja) * 2009-04-08 2010-10-28 Pioneer Electronic Corp 情報提供装置、情報提供方法、及び情報提供用プログラム
KR101544246B1 (ko) 2009-05-07 2015-08-12 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린 유사체의 고체 제제
CA2777070C (en) * 2010-06-03 2019-11-05 United Therapeutics Corporation Treprostinil production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057701A1 (en) * 1999-03-31 2000-10-05 United Therapeutics Corporation Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension

Also Published As

Publication number Publication date
US9199908B2 (en) 2015-12-01
US20050282901A1 (en) 2005-12-22
JP2007501281A (ja) 2007-01-25
CA2959852A1 (en) 2005-01-27
CN102697790A (zh) 2012-10-03
CA2526534C (en) 2011-07-12
WO2005007081A3 (en) 2005-04-14
US9878972B2 (en) 2018-01-30
ES2622471T3 (es) 2017-07-06
EP1628654B2 (en) 2019-12-04
US9624156B2 (en) 2017-04-18
CN101780092A (zh) 2010-07-21
US20110118213A1 (en) 2011-05-19
JP5043433B2 (ja) 2012-10-10
EP1628654A2 (en) 2006-03-01
US20200181057A1 (en) 2020-06-11
US20150005374A1 (en) 2015-01-01
CN1822826A (zh) 2006-08-23
US20130261187A1 (en) 2013-10-03
US10947177B2 (en) 2021-03-16
US20150259274A1 (en) 2015-09-17
EP2792353A2 (en) 2014-10-22
US20220289660A1 (en) 2022-09-15
EP1628654A4 (en) 2008-10-15
US20160030371A1 (en) 2016-02-04
US20180141891A1 (en) 2018-05-24
JP2012162539A (ja) 2012-08-30
EP1628654B1 (en) 2017-01-25
US20050085540A1 (en) 2005-04-21
US20220024845A1 (en) 2022-01-27
US8536363B2 (en) 2013-09-17
US20190345091A1 (en) 2019-11-14
KR20060021862A (ko) 2006-03-08
US11292758B2 (en) 2022-04-05
US20160355455A1 (en) 2016-12-08
US20080249167A1 (en) 2008-10-09
CA2851309C (en) 2017-04-18
WO2005007081A2 (en) 2005-01-27
CA2851309A1 (en) 2005-01-27
US9422223B2 (en) 2016-08-23
EP2792353A3 (en) 2015-03-25
CN101780092B (zh) 2012-07-04
US7544713B2 (en) 2009-06-09
US20120295980A1 (en) 2012-11-22
CA2526534A1 (en) 2005-01-27
WO2005007081A9 (en) 2017-01-26
US20070078095A1 (en) 2007-04-05
CA2736406C (en) 2014-11-18
US8252839B2 (en) 2012-08-28
CN101265226B (zh) 2013-04-24
US20070082948A1 (en) 2007-04-12
US8232316B2 (en) 2012-07-31
EP2792353B1 (en) 2018-02-28
CN100558351C (zh) 2009-11-11
US7384978B2 (en) 2008-06-10
US20160051505A1 (en) 2016-02-25
US8410169B2 (en) 2013-04-02
CN101265226A (zh) 2008-09-17
US9050311B2 (en) 2015-06-09
ES2670872T3 (es) 2018-06-01
ES2622471T5 (es) 2020-07-23
CA2736406A1 (en) 2005-01-27
US7417070B2 (en) 2008-08-26
US9278901B2 (en) 2016-03-08
US20070078182A1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
KR101072339B1 (ko) 프로스타시클린 유사체의 전달을 위한 화합물 및 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090504

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101118

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20110811

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20110915

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20111005

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20111006

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20140923

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20140923

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20150827

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20150827

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20160831

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20160831

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20180918

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20180918

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20190917

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20190917

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20200928

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20210915

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20220818

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20241124

Termination category: Expiration of duration